A Novel Class of Multi‐substituted Diaryl Scaffold Derivatives Inhibit Glioblastoma Progression by Targeting CD155
Advanced Science · 2025-08 · 12 (32)
DOI: 10.1002/advs.202506688 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 10.06.2025. Verfasst von Yong-Jian Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Glioblastoma, Receptors, Virus, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most formidable malignancy in the brain, characterized by a significant resistance to treatment. The immune targeting of glioblastoma stem cells (GSCs) holds great promise. In this study, structural modifications of the lead compound clofoctol is conducted and structure–activity relationship analyses are performed against GBM, yielding a novel blood‐brain barrier‐permeable compound, B7 , featuring a pivotal multi‐substituted diaryl scaffold. B7 demonstrates potent anti‐GBM effects, significantly inhibiting GSC proliferation, migration, and invasion. Notably, B7 inhibits tumor progression, specifically bolstered natural killer (NK) cell‐mediated cytotoxicity, and mitigates the immunosuppressive microenvironment in intracranial xenograft mice implanted with GBM cells and GSCs, as well as in cocultures of GSCs and NK‐92 cells. Mechanistically, these anti‐GBM effects of B7 are abolished by overexpression of poliovirus receptor cell adhesion molecule (CD155), both in vitro and in vivo . Further exploration reveals that B7 targets CD155 via interaction at five crucial binding sites, namely, L47, L108, L142, M110, and V115 residues. These interactions collectively contribute to the hydrophobic interaction energies within the B7 ‐CD155 complex, modulating the CD155/T cell immunoreceptor with Ig and ITIM domains/CD226 axis to reshape the NK cell‐mediated tumor immune microenvironment. In conclusion, this study establishes the therapeutic potential of B7 for glioma, synergistically targeting GSC biology and NK cell immunity for the treatment of GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
- Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China.
ORCID-Profile: Rui Liu
Förderung
- National Natural Science Foundation of China
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Wang, Y. J., Sun, T., Xue, S. T., Cai, Z. D., Yi, H., Lv, M., Kou, S. B., Liu, R., Peng, X. Z., & Li, Z. R. (2025). A Novel Class of Multi‐substituted Diaryl Scaffold Derivatives Inhibit Glioblastoma Progression by Targeting CD155. Advanced Science, 12(32). https://doi.org/10.1002/advs.202506688
Vancouver
Wang YJ, Sun T, Xue ST, Cai ZD, Yi H, Lv M, et al. A Novel Class of Multi‐substituted Diaryl Scaffold Derivatives Inhibit Glioblastoma Progression by Targeting CD155. Advanced Science. 2025;12(32). doi:10.1002/advs.202506688
BibTeX
@article{Wang2025,
author = {Wang, Yong-Jian and Sun, Ting and Xue, Si-Tu and Cai, Zhong-di and Yi, Hong and Lv, Miao and Kou, Shi-Bo and Liu, Rui and Peng, Xiao-Zhong and Li, Zhuo-Rong},
title = {A Novel Class of Multi‐substituted Diaryl Scaffold Derivatives Inhibit Glioblastoma Progression by Targeting CD155},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {32},
doi = {10.1002/advs.202506688}
}
EUVIMED